Cittanova M L, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P
Département d'Anesthésie-Réanimation, Hôpital Pitié-Salpêtrière, Paris, France.
Lancet. 1996 Dec 14;348(9042):1620-2. doi: 10.1016/s0140-6736(96)07588-5.
Hydroxyethylstarch used as a plasma-volume expander in brain-dead kidney donors has been suggested to induce osmotic-nephrosis-like lesions. We have studied its effect on kidney-transplant function.
52 patients who had received hydroxyethylstarch of iodinated contrast-media before brain death were excluded. 69 other brain-dead patients were prospectively included over 18 months and randomised into two groups. In the hydroxyethylstarch-gelatin group, patients received hydroxyethylstarch up to 33 mL/kg for colloid plasma-volume expansion, and afterwards received modified fluid gelatin. In the gelatin-only group, patients received only modified fluid gelatin as colloid plasma-volume expander. Multiple organs were procured in 29 cases, which included the kidneys in 27 cases (hydroxyethylstarch-gelatin 15, gelatin-only 12).
There were no significant differences in the characteristics of patients between the two groups of kidney donors or of recipients (except for a small imbalance in sex in the recipients). During the first 8 days after transplantation, nine of 27 (33%) patients required extrarenal haemodialysis or haemodiafiltration in the hydroxyethylstarch-gelatin group compared with one of 20 (5%) in the gelatin-only group (p = 0.029). Serum creatinine concentrations were significantly lower in the gelatin-only group than in the other group (p = 0.009). 10 days after transplantation, mean (SD) serum creatinine was, respectively, 145 (70) and 312 (259) mumol/L.
These data suggest that hydroxyethylstarch used as a plasma-volume expander in brain-dead donors impairs immediate renal function in kidney-transplant recipients.
有人提出,在脑死亡的肾供体中用作血浆容量扩充剂的羟乙基淀粉会诱发类似渗透性肾病的病变。我们研究了其对肾移植功能的影响。
排除52例在脑死亡前接受过碘造影剂羟乙基淀粉的患者。在18个月内前瞻性纳入了69例其他脑死亡患者,并随机分为两组。在羟乙基淀粉 - 明胶组中,患者接受高达33 mL/kg的羟乙基淀粉以进行胶体血浆容量扩充,之后接受改良液体明胶。在单纯明胶组中,患者仅接受改良液体明胶作为胶体血浆容量扩充剂。29例患者获取了多个器官,其中27例包括肾脏(羟乙基淀粉 - 明胶组15例,单纯明胶组12例)。
两组肾供体或受体的患者特征无显著差异(受体性别存在小的不平衡除外)。移植后的前8天,羟乙基淀粉 - 明胶组27例患者中有9例(33%)需要进行肾外血液透析或血液滤过,而单纯明胶组20例患者中有1例(5%)需要(p = 0.029)。单纯明胶组的血清肌酐浓度显著低于另一组(p = 0.009)。移植后10天,平均(标准差)血清肌酐分别为145(70)和312(259)μmol/L。
这些数据表明,在脑死亡供体中用作血浆容量扩充剂的羟乙基淀粉会损害肾移植受者的即时肾功能。